GET DAILY SIGNALSGrifols (GRFS) Posts Solid Q3 2026 Results with Margin Gains and Lower Leverage
Key Takeaways
- Grifols reported third-quarter 2026 revenue of EUR 2,040 million, up 8.4% year over year on a constant-currency basis, led by its Biopharma business.
- Adjusted EBITDA rose 9.8% to EUR 538 million, with the margin expanding 60 basis points to 26.4%.
- Net profit climbed 27.9% to EUR 162 million, bringing nine-month profit to EUR 390 million, up 28.4% year over year.
- Free cash flow before M&A reached EUR 208 million in the quarter, lifting nine-month free cash flow to EUR 298 million, up 59%.
- Net leverage fell below 4.0x to 3.98x, down from 4.2x a year earlier, while liquidity increased to EUR 2,140 million.
- For more detail on the company's key developments, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- To discover AI-driven trading ideas across the broader market, explore Trending AI Robots.
Earnings Context and Why It Matters
Grifols is a Barcelona-based global healthcare company and one of the world's leading producers of plasma-derived medicines. Its results offer a read on underlying demand for immunoglobulin (IG) therapies, which treat immune deficiencies and neurological conditions. The Q3 2026 report arrives as the company executes its Value Creation Plan, a multi-year effort centered on deleveraging, cash-flow generation, and margin recovery. Investors are watching closely because Grifols has been steadily reducing leverage from a peak of 5.5x in mid-2024. Continued weakness in the Chinese albumin market and the dissolution of its QuidelOrtho diagnostics joint business have weighed on segments, making Biopharma momentum and balance-sheet progress the central themes of this quarter's update. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Grifols reported third-quarter 2026 revenue of EUR 2,040 million, an increase of 8.4% at constant currency, driven by 10.3% growth in Biopharma. Adjusted EBITDA reached EUR 538 million, up 9.8%, with the margin expanding to 26.4%. For the first nine months of 2026, revenue totaled EUR 5,614 million (up 4.6%) and adjusted EBITDA reached EUR 1,392 million (up 5.0%), with a 24.8% margin, roughly 30 basis points higher than a year earlier.
Net profit rose 27.9% to EUR 162 million in the quarter. Free cash flow before M&A reached EUR 208 million, bringing nine-month free cash flow to EUR 298 million, EUR 110 million higher than the prior-year period. Net leverage declined to 3.98x from 4.2x a year earlier, and liquidity stood at EUR 2,140 million. The board approved an interim dividend of EUR 0.15 per share, payable in early December 2026.
By franchise, immunoglobulin revenue grew 11.3% at constant currency in the quarter, with subcutaneous IG up 40.3%. Alpha-1 and specialty proteins rose 18.2%, while albumin declined 13.2% amid continued pricing and inventory pressures in China. Diagnostics revenue fell on the QuidelOrtho joint-business dissolution. From what I see, the immunoglobulin trends stand out as particularly resilient here.
Market Reaction and Investor Sentiment
Shares of Grifols moved higher following the release, reflecting a broadly positive reception to margin expansion, stronger free cash flow, and the decline in leverage below 4.0x. Investors appeared to weigh the strength of the immunoglobulin franchise and improving profitability against ongoing softness in the Chinese albumin market and the Diagnostics decline tied to the QuidelOrtho joint-business dissolution. Management reiterated its full-year 2026 guidance, including an adjusted EBITDA margin target of 25%, which reinforced confidence in the outlook. The combination of accelerating Biopharma growth, a recovering balance sheet, and a reinstated interim dividend contributed to constructive sentiment even as segment-level headwinds persisted. I’m watching this closely as the deleveraging path continues to unfold.
Forward Outlook and Key Factors to Monitor
Looking ahead, Grifols reaffirmed its 2026 targets, including a full-year adjusted EBITDA margin of 25% and continued free cash flow growth. Management also flagged that Q4 2026 Biopharma growth may moderate as the company laps a strong prior-year sales quarter, and that some free cash flow conversion benefits in the third quarter may unwind in the fourth.
Several factors will shape the coming quarters. First, the trajectory of the immunoglobulin franchise remains the single most important driver, with subcutaneous IG continuing to grow rapidly. Second, the Chinese albumin market will be a key swing factor, as prescribing restrictions, elevated channel inventories, and pricing pressure have weighed on that franchise for multiple quarters.
Third, investors should monitor the ramp-up of Grifols Egypt, which is targeting roughly one million liters of plasma collection in 2026, as a longer-term supply-security initiative. Finally, the balance sheet remains in focus. With no significant debt maturities until the fourth quarter of 2028 following recent refinancing, attention will shift to whether Grifols can sustain its deleveraging trajectory while balancing shareholder returns such as the newly announced interim dividend. In my view, sustained cash flow generation will be the real test ahead.
Exploring Tickeron AI Tools in My Research
I often turn to Tickeron’s AI Screener when analyzing healthcare names like this one. It helps me quickly filter for patterns, fundamentals, and sector comparisons that would otherwise take hours to compile manually. The tool has become a regular part of how I spot ideas and confirm trends across the market, especially when tracking balance-sheet progress or franchise-specific growth.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GRFS in upward trend: 10-day moving average moved above 50-day moving average on October 27, 2026
The 10-day moving average for GRFS crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on GRFS as a result. In 59 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
GRFS moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where GRFS advanced for three days, in 194 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRFS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
GRFS broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GRFS entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.034) is normal, around the industry mean (-1.421). P/E Ratio (12.773) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (0.189) is also within normal values, averaging (5.738). Dividend Yield (0.042) settles around the average of (0.038) among similar stocks. GRFS's P/S Ratio (0.592) is slightly lower than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating fairly steady price growth. GRFS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of plasma-derived biological medicines
Industry PharmaceuticalsMajor
Advertisement